GlassScriptPhysician profile
Pranith N Perera
NPI 1831361591
$14,449.78
in general payments reported to CMS, 2019-2025
23 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,778 · 2020: $1,146 · 2021: $614 · 2022: $368 · 2023: $4,328 · 2024: $925 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $3,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $3,043.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $9,369.30 | 2019-2025 | Axios, General - Biliary Devices, Spyglass |
| Abbvie INC. | $1,803.16 | 2019-2025 | |
| Gi Supply, INC. | $1,161.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $432.21 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $354.30 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.36 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $189.20 | 2024-2025 | Sutab, Suflave |
| Pfizer INC. | $163.93 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $124.98 | 2024 | Voquezna |
| Celgene Corporation | $112.69 | 2022-2024 | Zeposia |
| Ambu INC. | $93.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $61.90 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $59.49 | 2022-2024 | Linzess |
| Gilead Sciences, INC. | $49.02 | 2025 | |
| Nestle Healthcare Nutrition INC. | $40.88 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $36.81 | 2022 | |
| Aimmune Therapeutics, INC. | $35.75 | 2024 | |
| Qol Medical, LLC | $28.85 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $26.55 | 2025 | |
| Genzyme Corporation | $26.39 | 2025 | |
| Madrigal Pharmaceuticals | $21.27 | 2024 | Resmetirom |
| Lilly USA, LLC | $19.24 | 2024 | Omvoh |
| Redhill Biopharma INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranith Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.